ANVS
HealthcareAnnovis Bio, Inc.
$3.80
+$0.15 (+4.11%)
Jan 5, 2026
Price History (1Y)
Analysis
Annovis Bio, Inc. is a biotechnology company in the healthcare sector with a market capitalization of $100.71 million and 8 employees. The company's financial health is marked by significant losses, with a net income of -$24,884,444 over the trailing twelve months. Annovis Bio has an operating margin, gross margin, and profit margin of 0.0%, indicating that it has not generated any revenue or profit from its operations. The returns on equity and assets are negative at -246.1% and -105.9%, respectively. However, the company's balance sheet shows a cash position of $15.29 million. Annovis Bio's valuation metrics include a forward P/E ratio of -3.33, indicating that the market expects significant losses to continue. The price-to-book ratio is 5.83, and the company does not have a dividend yield or payout ratio. The beta of 1.46 suggests that the stock has higher volatility compared to the overall market.
This analysis is AI-generated for informational purposes only and should not be considered financial advice. Data may be delayed or inaccurate. Always do your own research and consult a qualified financial advisor before making investment decisions.
About Annovis Bio, Inc.
Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration in the United States. The company's lead product candidate is Buntanetap, which is in phase 2/3 to treat alzheimer's disease, as well as in phase 3 to treat parkinson's disease; and is in phase 2 clinical trial to treat lewy body dementia. It also develops ANVS405, which is in phase 2 and 3 clinical trials for the treatment of traumatic brain injury and/or stroke; and ANVS301, which finished phase 1 clinical trial to treat later stages of alzheimer's disease and dementia. The company was incorporated in 2008 and is headquartered in Malvern, Pennsylvania.
Visit website →Key Statistics
- Market Cap
- $100.71M
- P/E Ratio
- N/A
- 52-Week High
- $5.57
- 52-Week Low
- $1.11
- Avg Volume
- 1.95M
- Beta
- 1.46
Company Info
- Industry
- Biotechnology
- Exchange
- NYQ
- Country
- United States
- Employees
- 8